News & Events:MGTA

Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at...

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING. * SAYS PUBLIC OFFERING OF 7.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE Source text for Eikon: Further company coverage:

Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering.

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS LAUNCHES PROPOSED PUBLIC OFFERING. * MAGENTA THERAPEUTICS (MGTA) - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF ITS COMMON STOCK. * MAGENTA THERAPEUTICS (MGTA) - INTENDS TO USE PROCEEDS TO ADVANCE CLINICAL, EARLIER STAGE PROGRAMS Source text for Eikon: Further company coverage:

Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering.

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS AND BEAM THERAPEUTICS ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE MGTA-117 AS CONDITIONING REGIMEN FOR BASE EDITING THERAPIES. * MAGENTA THERAPEUTICS (MGTA) - CO, BEAM THERAPEUTICS ANNOUNCED NON-EXCLUSIVE COLLABORATION AGREEMENT TO EVALUATE POTENTIAL UTILITY OF MGTA-117 Source text for Eikon: Further company coverage:

– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – Magenta Therapeutics (MGTA) and Beam Therapeutics (BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted ADC...

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PROVIDES PORTFOLIO UPDATE: STEM CELL MOBILIZATION AND CONDITIONING PROGRAMS PRIORITIZED AND ADVANCING TOWARD CLINICAL MILESTONES. * Magenta Therapeutics Inc (MGTA) - MGTA-145 FIRST-LINE MOBILIZATION PROGRAM TO MOVE INTO PHASE 2 STUDIES IN AUTOLOGOUS AND ALLOGENEIC PATIENTS IN 2020.

— MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program®/Be The Match® — — based conditioning program on track for initial clinical data in 2021; research and clinical collaboration with AVROBIO announced May 2020 to jointly evaluate pote...

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS ANNOUNCES COLLABORATION WITH THE NATIONAL MARROW DONOR PROGRAM/BE THE MATCH TO ADVANCE DEVELOPMENT OF MGTA-145 FOR FIRST-LINE MOBILIZATION OF STEM CELLS FROM HEALTHY DONORS AND SUBSEQUENT PATIENT TRANSPLANT.

Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers Plan to initiate a Phase II trial of MGTA-145 in matched related donors for patients undergoing allogeneic transplant CAMBRIDGE, Mass.

Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11th, 2020.

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PRESENTS DATA SUPPORTING IMMUNE RESET FOR AUTOIMMUNE DISEASES Source text for Eikon: Further company coverage:

-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- MGTA-145 Phase 1 clinical data for stem cell mobilization provide a strong rationale for studying in patients with autoimmune diseases -- CAMBRIDGE, Mass. “Millions of patients worldwide live with debilitating autoimmune diseases.

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PRESENTS DATA AT ANNUAL MEETING OF AMERICAN SOCIETY OF GENE AND CELL THERAPY DEMONSTRATING CELLS MOBILIZED WITH MGTA-145 IN A PHASE I TRIAL ARE EFFECTIVE IN GENE THERAPY SETTINGS. * MAGENTA THERAPEUTICS (MGTA) - MGTA-145 WAS SHOWN TO BE RAPID, RELIABLE, EFFICIENT AND G-CSF-FREE METHOD TO OBTAIN HIGH NUMBERS OF FUNCTIONAL HSCS IN PHASE 1 TRIAL.

– MGTA-145 was shown to be a rapid, reliable, efficient and G-CSF-free method to obtain high numbers of functional HSCs in a Phase 1 trial; the cells could be gene modified and engraft in animals.

Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER FINANCIAL RESULTS. * Magenta Therapeutics Inc (MGTA) - NET LOSS WAS $20.0 MILLION FOR Q1 OF 2020, COMPARED TO NET LOSS OF $14.8 MILLION FOR Q1 OF 2019 Source text for Eikon: Further company coverage:

– MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 – – Announced research and clinical collaboration with AVROBIO to evaluate potential utility of MGTA-117 antibody-drug conjugate as conditioning regimen in gene therapy setting – – Completed dosing in Phase 1 MGTA-145 trial, demonstrating rapi...

AVROBIO Inc (AVRO): * MAGENTA THERAPEUTICS AND AVROBIO ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE AS A POTENTIAL CONDITIONING REGIMEN FOR LENTIVIRAL GENE THERAPIES. * MAGENTA THERAPEUTICS INC (MGTA) - CO & AVROBIO WILL JOINTLY EVALUATE MGTA-117 IN CONJUNCTION WITH ONE OR MORE OF AVROBIO'S INVESTIGATIONAL GENE THERAPIES.

Collaboration focuses on advancing innovation with antibody-drug conjugate-based conditioning for lentiviral gene therapies Under the collaboration, Magenta and AVROBIO (AVRO) will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO’s investigational gene therapies Each company will retain all commercial rights to their respective programs Magenta to hold business update conference ca...